natgillin/translations-raw huggingface dataset:
It is recommended that the medicine be taken on an empty stomach, preferably at bedtime. 
Priporočljivo je, da se jemlje na prazen želodec, po možnosti pred spanjem.
Patients should take the medicine regularly and avoid missing doses. 
Bolniki morajo zdravilo jemati redno in odmerkov ne smejo izpuščati.
The company that markets the medicine will ensure that all doctors expected to prescribe the medicine are provided with an educational pack that includes information on the increased risk of kidney disease with tenofovir disoproxil-containing medicines such as this one. 
Družba, ki trži zdravilo, bo zagotovila, da bodo vsi zdravniki, ki naj bi predpisovali zdravilo, prejeli izobraževalno gradivo, ki bo vsebovalo informacije o povečanem tveganju ledvične bolezni pri zdravilih,
All three active substances block the activity of reverse transcriptase, an enzyme produced by HIV that allows it to reproduce itself in the cells it has infected. 
Vse tri zdravilne učinkovine zavirajo dejavnost reverzne transkriptaze, tj. encima, ki ga tvori virus HIV in ki mu omogoča razmnoževanje v okuženih celicah.
For more information about treatment with this medicine, read the package leaflet (also part of the EPAR) or contact your doctor or pharmacist. 
Za več informacij o zdravljenju s tem zdravilom preberite navodilo za uporabo (ki je prav tako del EPAR) ali se posvetujte z zdravnikom ali farmacevtom.
Studies on the benefits and risks of the active substance in the approved use have already been carried out with the reference medicine, Atripla, and do not need to be repeated for Efavirenz/Emtricitabine/Tenofovir disoproxil Zentiva. 
Študije o koristih in tveganjih zdravilne učinkovine pri dovoljenih uporabah so že bile izvedene z referenčnim zdravilom Atripla, zato jih ni treba ponoviti za zdravilo Efavirenz/emtricitabin/dizoproksiltenofovirat Zentiva.
Because Efavirenz/Emtricitabine/Tenofovir disoproxil Zentiva is a generic medicine and is bioequivalent to the reference medicine, its benefits and risks are taken as being the same as the reference medicine's. 
Ker je zdravilo Efavirenz/emtricitabin/dizoproksiltenofovirat Zentiva generično zdravilo in je biološko enakovredno referenčnemu zdravilu, so njegove koristi in tveganja enaki kot pri referenčnem zdravilu.
Efavirenz/Emtricitabine/Tenofovir disoproxil Zentiva is a medicine used to treat adults infected with human immunodeficiency virus-1 (HIV-1), a virus that causes acquired immune deficiency syndrome (AIDS). 
Zdravilo Efavirenz/emtricitabin/dizoproksiltenofovirat Zentiva se uporablja za zdravljenje odraslih, ki so okuženi z virusom človeške imunske pomanjkljivosti tipa-1 (HIV-1), tj. virusom, ki povzroča sindrom pridobljene imunske pomanjkljivosti (aids).
Efavirenz/Emtricitabine/Tenofovir disoproxil Zentiva keeps the amount of HIV in the blood at a low level. 
Zdravilo Efavirenz/emtricitabin/dizoproksiltenofovirat Zentiva ohranja nizko raven virusa HIV v krvi.
This is a summary of the European public assessment report (EPAR) for Efavirenz/Emtricitabine/Tenofovir disoproxil Zentiva. 
To je povzetek evropskega javnega poročila o oceni zdravila (EPAR) za zdravilo Efavirenz/emtricitabin/dizoproksiltenofovirat Zentiva.
For practical information about using Efavirenz/Emtricitabine/Tenofovir disoproxil Zentiva, patients should read the package leaflet or contact their doctor or pharmacist. 
Za praktične informacije o uporabi zdravila Efavirenz/emtricitabin/dizoproksiltenofovirat Zentiva naj bolniki preberejo navodilo za uporabo ali se posvetujejo z zdravnikom ali farmacevtom.
What is Efavirenz/Emtricitabine/Tenofovir disoproxil Zentiva and what is it used for? 
Kaj je zdravilo Efavirenz/emtricitabin/dizoproksiltenofovirat Zentiva in za kaj se uporablja?
This medicine contains three active substances: efavirenz, which is a non-nucleoside reverse transcriptase inhibitor (NNRTI); emtricitabine, which is a nucleoside reverse transcriptase inhibitor; and tenofovir disoproxil, which is a ‘prodrug' of tenofovir, meaning that it is converted into the active substance tenofovir in the body. 
To zdravilo vsebuje tri zdravilne učinkovine: efavirenz, ki je nenukleozidni zaviralec reverzne transkriptaze (NNRTI), emtricitabin, ki je nukleozidni zaviralec reverzne transkriptaze, in dizoproksiltenofovirat, ki je predzdravilo tenofovirja, kar pomeni, da se v zdravilno učinkovino tenofovir pretvori v telesu.
This medicine should not be taken at the same time as other medicines that contain efavirenz, emtricitabine or tenofovir disoproxil, or lamivudine (another antiviral medicine). 
To zdravilo se ne sme jemati sočasno z drugimi zdravili, ki vsebujejo efavirenz, emtricitabin, dizoproksiltenofovirat ali lamivudin (tudi protivirusno zdravilo).
Other information about Efavirenz/Emtricitabine/Tenofovir disoproxil Zentiva 
Druge informacije o zdravilu Efavirenz/emtricitabin/dizoproksiltenofovirat Zentiva
Efavirenz/Emtricitabine/Tenofovir disoproxil Zentiva 
Efavirenz/emtricitabin/dizoproksiltenofovirat Zentiva efavirenz/emtricitabin/dizoproksiltenofovirat
Date of first authorisation: 28 September 2012 Date of latest renewal: 26 July 2017 
Datum prve odobritve: 28. september 2012 Datum zadnjega podaljšanja: 26. julij 2017
Then take the next dose as usual. 
Naslednjega dne vzemite odmerek kot običajno.
You can inhale this medicine anytime before or after food or drink. 
To zdravilo lahko inhalirate kadarkoli, pred ali po uživanju hrane oziroma pijače.
Children and adolescents Do not give this medicine to children or adolescents below the age of 18 years. 
Tega zdravila ne dajajte otrokom ali mladostnikom, ki so stari manj kot 18 let.
Therefore the frequency was calculated from clinical trial experience. 
Iz tega razloga je pogostnost izračunana na podlagi izkušenj v kliničnih preskušanjih.
• Painful and frequent urination 
• boleče in pogosto uriniranje
• Voice alteration (hoarseness) 
• sprememba glasu (hripavost)
The most common anticholinergic adverse reaction was dry mouth (2.4%). 
Najbolj pogost antiholinergični neželeni učinek so bila suha usta (2,4 %).
If a dose is missed, the next dose should be taken as soon as possible. 
V primeru izpuščenega odmerka je treba naslednji odmerek vzeti čimprej.
• Whenever the risk management system is modified, especially as the result of new information being received that may lead to a signifcant change to the benefit/risk profile or as the result of an important (pharmacovigilance or risk minimisation) milestone being reached. 
• ob vsakršni spremembi sistema za obvladovanje tveganj, zlasti kadar je tovrstna sprememba posledica prejema novih informacij, ki lahko privedejo do znatne spremembe razmerja med koristmi in tveganji, ali kadar je ta sprememba posledica tega, da je bil dosežen pomemben mejnik (farmakovigilančni ali povezan z zmanjševanjem tveganja).
Elderly people You can use this medicine if you are aged 75 years and over at the same dose as for other adults. 
Starejši ljudje Če ste stari 75 let ali več, lahko uporabljate to zdravilo v enakem odmerku kot drugi odrasli.
This medicine contains lactose. 
To zdravilo vsebuje laktozo.
Other effects 
Drugi učinki
In addition, the corresponding frequency category for each adverse reaction is based on the following convention: very common (≥1/10); common (≥1/100 to <1/10); uncommon (≥1/1,000 to <1/100); rare (≥1/10,000 to <1/1,000); very rare (<1/10,000); not known (cannot be estimated from the available data). 
Pri tem razvrstitev posameznega neželenega učinka v ustrezno kategorijo pogostnosti temelji na naslednjem dogovoru: zelo pogosti (≥1/10); pogosti (≥1/100 do <1/10); občasni (≥1/1.000 do <1/100); redki (≥1/10.000 do <1/1.000); zelo redki (<1/10.000); neznana (ni mogoče oceniti iz razpoložljivih podatkov).
- COPD is a long-term disease and you should use this medicine every day and not only when you have breathing problems or other symptoms of COPD. 
- KOPB je dolgotrajna bolezen in to zdravilo morate uporabljati vsak dan, ne le takrat, ko težko dihate ali imate katerega od drugih simptomov KOPB.
In both studies, the percentage of patients experiencing a moderate or severe exacerbation (defined as requiring treatment with systemic corticosteroids and/or antibiotics or hospitalisation) was reduced. 
V obeh študijah je prišlo do zmanjšanja odstotka bolnikov, pri katerih je prišlo do zmernega oziroma hudega poslabšanja (ki je bilo opredeljeno s potrebo po zdravljenju s sistemskimi kortikosteroidi in/ali z antibiotiki ali s hospitalizacijo).
There are no data from the use of this medicine in pregnant women and it is not known whether the active substance of this medicine passes into human milk. 
O uporabi tega zdravila v nosečnosti ni na voljo nobenih podatkov in prav tako ni znano, ali zdravilna učinkovina tega zdravila prehaja v materino mleko.
Some side effects may be serious, but the frequency of these side effects is not known (frequency cannot be estimated from the available data) 
Nekateri neželeni učinki so lahko resni, vendar njihova pogostnost ni znana (pogostnosti ni mogoče oceniti iz razpoložljivih podatkov)
• High level of blood sugar (hyperglycaemia: typical symptoms include excessive thirst or hunger and frequent urination) 
• zvišana raven sladkorja v krvi (hiperglikemija: značilni simptomi pri tem so huda žeja ali lakota in pogosto odvajanje vode)
Pharmacotherapeutic group: Drugs for obstructive airway diseases, anticholinergics, ATC code: R03BB06 
Farmakoterapevtska skupina: zdravila za obstruktivne pljučne bolezni, antiholinergiki, oznaka ATC: R03BB06
Gastrointestinal effects including gastroenteritis and dyspepsia were also observed. 
Opažali so še gastrointestinalne učinke, med drugim gastroenteritis in dispepsijo.
The European Medicines Agency has waived the obligation to submit the results of studies with Tovanor Breezhaler in all subsets of the paediatric population in COPD (see section 4.2 for information on paediatric use). 
Evropska agencija za zdravila je odstopila od zahteve za predložitev rezultatov študij z zdravilom Tovanor Breezhaler za vse podskupine pediatrične populacije s KOPB (za podatke o uporabi pri pediatrični populaciji glejte poglavje 4.2).
This medicine blocks the tightening of these muscles in the lungs, making it easier for air to get in and out of the lungs. 
To zdravilo zmanjša napetost teh mišic v pljučih, tako da zrak lažje vstopi v pljuča in izstopi iz njih.
If you use more Tovanor Breezhaler than you should If you have inhaled too much of this medicine or if someone else accidentally uses your capsules, you must immediately either tell your doctor or go to the nearest emergency unit. 
Če ste uporabili večji odmerek zdravila Tovanor Breezhaler, kot bi smeli Če ste vdihnili preveč tega zdravila ali če kdo drug pomotoma uporabi vaše kapsule, takoj obvestite zdravnika ali pojdite do najbližjega oddelka za nujno pomoč.
1) More frequent for glycopyrronium than placebo in the 12 months database only. 
1) Bolj pogosti pri uporabi glikopironija kot pri uporabi placeba samo v 12-mesečni podatkovni bazi.
High doses of glycopyrronium may lead to anticholinergic signs and symptoms for which symptomatic treatment may be indicated. 
Visoki odmerki glikopironija lahko povzročijo antiholinergične znake in simptome, pri katerih je indicirano simptomatsko zdravljenje.
Excipient(s) with known effect: Each capsule contains 23.6 mg lactose (as monohydrate). 
Pomožna(e) snov(i) z znanim učinkom: Ena kapsula vsebuje 23,6 mg laktoze (v obliki monohidrata).
The capsules must be administered only using the Tovanor Breezhaler inhaler (see section 6.6). 
Kapsule so namenjene samo uporabi z inhalatorjem Tovanor Breezhaler (glejte poglavje 6.6).
Glycopyrronium has no or negligible influence on the ability to drive and use machines. 
Glikopironij nima vpliva ali ima zanemarljiv vpliv na sposobnost vožnje in upravljanja strojev.
Driving and using machines It is unlikely that this medicine will affect your ability to drive and use machines. 
Vpliv na sposobnost upravljanja vozil in strojev Malo verjetno je, da bi to zdravilo vplivalo na vašo sposobnost upravljanja vozil in strojev.
Insufficient pharmacokinetic data is available for other ethnicities or races. 
O uporabi pri pripadnikih drugih etničnih skupin in ras ni na voljo dovolj farmakokinetičnih podatkov.
The recommended dose is the inhalation of the content of one capsule once daily using the Tovanor Breezhaler inhaler. 
Priporočeni odmerek je inhalacija vsebine ene kapsule enkrat na dan z uporabo inhalatorja Tovanor Breezhaler.
• Swelling mainly of the tongue, lips, face or throat (possible signs of angioedema) If you get any of these side effects, tell your doctor immediately. 
• otekanje, zlasti jezika, ustnic, obraza ali grla (možni znaki angioedema) Če imate katerega od navedenih neželenih učinkov, takoj obvestite svojega zdravnika.
The safety profile is further characterised by other symptoms related to the anticholinergic effects, including signs of urinary retention, which were uncommon. 
Varnostne lastnosti zdravila označujejo še drugi simptomi, ki so povezani z antiholinergičnimi učinki, med katerimi so znaki zastoja urina, ki so bili občasni.
• Difficulty breathing with wheezing or coughing (signs of paradoxical bronchospasm) 
• oteženo dihanje s piskajočim dihanjem ali kašljem (znaki paradoksnega bronhospazma)
• Feeling of pressure or pain in the cheeks and forehead 
• občutek pritiska ali bolečine pod očmi ali v čelu
• Stomach discomfort after meals 
• bolečine v trebuhu po obroku
Elimination After intravenous administration of [ 
Izločanje Po intravenskem odmerjanju s [
Tovanor Breezhaler once daily has also shown a statistically significant effect on health-related quality of life measured using the St. George's Respiratory Questionnaire (SGRQ). 
Odmerjanje zdravila Tovanor Breezhaler enkrat dnevno je statistično značilno vplivalo tudi na z zdravjem povezano kakovost življenja, ki so jo ocenili s pomočjo vprašalnika St. George's Respiratory Questionnaire (SGRQ).
These were reported voluntarily from a population of uncertain size, and it is therefore not always possible to reliably estimate the frequency or establish a causal relationship to drug exposure. 
Ker gre za spontano sporočene neželene učinke iz populacije nedoločljive velikosti, ni vedno mogoče zanesljivo oceniti njihove pogostnosti ali ugotoviti vzročne povezanosti z izpostavljenostjo zdravilu.
No new cases of dry mouth were reported in months 7-12. 
V 7.-12. mesecu študije niso poročali o novih primerih suhih ust.
How to inhale Tovanor Breezhaler - In this pack, you will find an inhaler and capsules (in blisters) that contain the medicine as inhalation powder. 
Kako inhalirati zdravilo Tovanor Breezhaler - V škatli boste našli inhalator in kapsule (v pretisnih omotih), ki vsebujejo zdravilo v obliki praška za inhaliranje.
Some elderly patients above 75 years of age experienced headache (frequency common) and urinary tract infection (frequency common). 
Pri nekaterih starejših bolnikih, ki so bili stari več kot 75 let, je prišlo do glavobola (pogosto) in okužbe sečil (pogosto).
• Pain in muscles, bones or joints of the chest 
• bolečine v mišicah, kosteh ali sklepih prsnega koša
There are no data from the use of Tovanor Breezhaler in pregnant women. 
Podatkov o uporabi zdravila Tovanor Breezhaler pri nosečnicah ni.
How long to continue your treatment with Tovanor Breezhaler - Keep using this medicine for as long as your doctor tells you. 
Kako dolgo je treba nadaljevati z uporabo zdravila Tovanor Breezhaler - Zdravljenje s tem zdravilom nadaljujte tako dolgo, kot vam naroči zdravnik.
3H]-labelled glycopyrronium bromide to humans, the mean urinary excretion of radioactivity in 48 hours amounted to 85% of the dose. 
3H] označenega glikopironijevega bromida pri ljudeh se je v 48 urah v urinu izločilo povprečno 85 % radioaktivno označenega odmerka.
Tovanor Breezhaler 44 micrograms once daily can be safely used in all age and body weight groups. 
Zdravilo Tovanor Breezhaler v odmerku 44 mikrogramov enkrat na dan je mogoče varno uporabljati v vseh starostnih skupinah in kategorijah telesne mase bolnikov.
Hydroxylation resulting in a variety of mono-and bis-hydroxylated metabolites and direct hydrolysis resulting in the formation of a carboxylic acid derivative (M9) were seen. 
Opažali so hidroksilacijo, s katero nastajajo različni monohidroksilirani in dihidroksilirani presnovki, in direktno hidrolizo, s katero nastaja derivat s karboksilno kislino (M9).
About 90% of systemic exposure following inhalation is due to lung absorption and 10% is due to gastrointestinal absorption. 
K celotni sistemski izpostavljenosti učinkovini po inhalaciji prispeva 90 % pljučna absorpcija, 10 % pa gastrointestinalna absorpcija.
If signs suggesting allergic reactions occur, in particular, angioedema (including difficulties in breathing or swallowing, swelling of the tongue, lips, and face), urticaria or skin rash, treatment should be discontinued immediately and alternative therapy instituted. 
Če se pojavijo znaki, ki kažejo na alergijsko reakcijo, zlasti angioedem (vključno z oteženim dihanjem ali požiranjem, otekanjem jezika, ustnic in obraza), urtikarija ali izpuščaj, je treba zdravljenje takoj ukiniti in uvesti drugo zdravilo.
Renal elimination of parent drug accounts for about 60 to 70% of total clearance of systemically available glycopyrronium whereas non-renal clearance processes account for about 30 to 40%. 
Izločanje nespremenjene učinkovine skozi ledvice znaša približno 60 % do 70 % celotnega očistka sistemsko prisotnega glikopironija, medtem ko procesi izločanja učinkovine po drugih poteh (neledvični očistek) prispevajo približno 30 % do 40 %.
There were no major differences in total systemic exposure (AUC) between Japanese and Caucasian subjects following inhalation of glycopyrronium bromide. 
Med Japonci in belci ni bilo večjih razlik v celotni sistemski izpostavljenosti (AUC) po inhalaciji glikopironijevega bromida.
If you have questions about how long to continue your treatment with this medicine, talk to your doctor or pharmacist. 
Če vas zanima, kako dolgo je treba nadaljevati z uporabo tega zdravila, se pogovorite s svojim zdravnikom ali farmacevtom.
Glycopyrronium should only be used during pregnancy if the expected benefit to the patient justifies the potential risk to the foetus. 
Glikopironij je v nosečnosti mogoče uporabiti samo v primeru, da pričakovana korist za bolnico upravičuje potencialno tveganje za plod.
Each pack contains a device called an inhaler, together with capsules in blisters. 
Eno pakiranje vsebuje pripomoček, ki se imenuje inhalator, skupaj s kapsulami v pretisnih omotih.
- The other ingredients of the inhalation powder are lactose monohydrate and magnesium stearate. 
- Drugi sestavini inhalacijskega praška sta laktoza monohidrat in magnezijev stearat.
Each blister strip contains either 6 or 10 hard capsules. 
Vsak pretisni omot vsebuje bodisi 6 ali 10 trdih kapsul.
• Rash, itching, hives, difficulty breathing or swallowing, dizziness (possible signs of allergic reaction) 
• izpuščaj, srbenje, koprivnica, oteženo dihanje ali požiranje, omotičnost (možni znaki alergijske reakcije)
Adverse reactions reported during the first six months of two pooled pivotal Phase III trials of 6 and 12 months duration are listed by MedDRA system organ class (Table 1). 
Neželeni učinki, o katerih so poročali v prvih šestih mesecih dveh ključnih združenih preskušanj faze III, ki sta trajali 6 oziroma 12 mesecev, so navedeni po MedDRA klasifikaciji organskih sistemov (preglednica 1).
This will also help you to remember to use it. 
Tako se boste tudi laže spomnili, da morate vzeti zdravilo.
Dry mouth was reported mainly during the first 4 weeks of treatment with a median duration of four weeks in the majority of patients. 
O suhih ustih so poročali predvsem v prvih 4 tednih zdravljenja.
COPD exacerbation data was collected in the 6- and 12-month pivotal studies. 
Podatki o akutnih poslabšanjih KOPB so bili zbrani v dveh ključnih študijah: 6-mesečni in 12mesečni.
Based on the magnitude of these changes, no clinically relevant drug interaction is expected when glycopyrronium is co-administered with cimetidine or other inhibitors of organic cation transport. 
Glede na velikost teh sprememb ni pričakovati klinično pomembnih interakcij pri sočasni uporabi glikopironija in cimetidina ali drugih zaviralcev transporta organskih kationov.
Do not use this medicine after the expiry date which is stated on the carton and blister after “EXP”. 
Tega zdravila ne smete uporabljati po datumu izteka roka uporabnosti, ki je naveden na škatli in pretisnem omotu poleg oznake "Uporabno do"/"EXP".
Patients should be informed about the signs and symptoms of acute narrow-angle glaucoma and should be informed to stop using Tovanor Breezhaler and to contact their doctor immediately should any of these signs or symptoms develop. 
Bolnike je treba seznaniti z znaki in simptomi akutnega glavkoma zaprtega zakotja in jim naročiti, naj v primeru razvoja teh simptomov ali znakov prenehajo uporabljati zdravilo Tovanor Breezhaler in takoj obvestijo svojega zdravnika.
• Musculoskeletal pain 
• mišičnoskeletne bolečine
The elimination pattern suggests sustained lung absorption and/or transfer of glycopyrronium into the systemic circulation at and beyond 24 hours after inhalation. 
Način izločanja kaže, da potekata absorpcija učinkovine v pljučih in/ali prehod glikopironija v sistemski krvni obtok vseh 24 ur in še dlje po inhalaciji zdravila.
The majority of the reports of dry mouth were suspected to be related to the medicinal product and were mild, with none being severe. 
Pri večini poročil o primerih suhih ust je šlo za sum na vzročno povezavo z zdravilom, simptomi pa so bili večinoma blago izraženi, v nobenem primeru ni šlo za hudo izraženost.
• Tovanor Breezhaler capsules must always be stored in the blister card and only removed immediately before use. 
• Tovanor Breezhaler kapsule vedno shranjujte v pretisnem omotu in jih vzemite iz njega šele tik pred uporabo.
Following oral inhalation using the Tovanor Breezhaler inhaler, glycopyrronium was rapidly absorbed and reached peak plasma levels at 5 minutes post dose. 
Po peroralni inhalaciji zdravila s pomočjo inhalatorja Tovanor Breezhaler se je glikopironij hitro absorbiral in dosegel najvišjo koncentracijo v plazmi 5 minut po odmerjanju.
Reproduction studies and other data in animals do not indicate a concern regarding fertility in either males or females (see section 5.3). 
Rezultati študij vpliva na sposobnost razmnoževanja in drugi podatki iz študij na živalih ne vzbujajo pomislekov glede plodnosti tako pri moških kot pri ženskah (glejte poglavje 5.3).
It has a rapid onset of action as evidenced by observed receptor association/dissociation kinetic parameters and the onset of action after inhalation in clinical studies. 
Glikopironijev bromid ima hiter začetek delovanja, kar dokazujejo zabeleženi parametri kinetike asociacije/disociacije in čas, ki je bil potreben za začetek delovanja po inhalaciji zdravila v kliničnih študijah.
In a clinical study in healthy volunteers, cimetidine, an inhibitor of organic cation transport which is thought to contribute to the renal excretion of glycopyrronium, increased total exposure (AUC) to glycopyrronium by 22% and decreased renal clearance by 23%. 
V klinični študiji z zdravimi prostovoljci je cimetidin, zaviralec transporta organskih kationov, ki je domnevno vpleten v izločanje glikopironija preko ledvic, povečal skupno izpostavljenost (AUC) glikopironiju za 22 %, njegov ledvični očistek pa je zmanjšal za 23 %.
Patients with a history of cardiovascular disease 
Bolniki z anamnezo kardiovaskularne bolezni
What Tovanor Breezhaler is and what it is used for What you need to know before you use Tovanor Breezhaler How to use Tovanor Breezhaler Possible side effects 
Kaj je zdravilo Tovanor Breezhaler in za kaj ga uporabljamo Kaj morate vedeti, preden boste uporabili zdravilo Tovanor Breezhaler Kako uporabljati zdravilo Tovanor Breezhaler Možni neželeni učinki
However in 40% of cases symptoms continued for the entire 6month period. 
Mediana vrednost trajanja je bila pri večini bolnikov štiri tedne, v 40 % primerov pa je bil simptom prisoten celotno 6-mesečno obdobje.